Press coverage about Albireo Pharma (NASDAQ:ALBO) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Albireo Pharma earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.141956684355 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Albireo Pharma, Inc. (ALBO) Expected to Announce Quarterly Sales of $55.00 Million (americanbankingnews.com)
- $3.81 Earnings Per Share Expected for Albireo Pharma, Inc. (ALBO) This Quarter (americanbankingnews.com)
- Albireo to Present at H.C. Wainwright Global Life Sciences Conference (pharmiweb.com)
- Albireo Pharma, Inc. to Post Q1 2018 Earnings of $3.57 Per Share, Wedbush Forecasts (ALBO) (americanbankingnews.com)
- Albireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
ALBO has been the subject of a number of recent research reports. Wedbush reiterated a “buy” rating on shares of Albireo Pharma in a research note on Wednesday, January 3rd. Zacks Investment Research upgraded Albireo Pharma from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Monday, January 8th. BidaskClub upgraded Albireo Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, January 31st. ValuEngine upgraded Albireo Pharma from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Needham & Company LLC lifted their price objective on Albireo Pharma to $50.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $59.50.
Albireo Pharma (NASDAQ:ALBO) last posted its earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.23. equities research analysts expect that Albireo Pharma will post 0.77 earnings per share for the current year.
In other news, major shareholder Phase4 Partners Ltd sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $34.44, for a total transaction of $3,444,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 275,000 shares of the stock in a transaction that occurred on Thursday, January 25th. The stock was purchased at an average price of $33.00 per share, for a total transaction of $9,075,000.00. The disclosure for this purchase can be found here. 22.30% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Albireo Pharma (ALBO) Share Price” was first posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://baseballnewssource.com/2018/04/05/albireo-pharma-albo-given-daily-media-impact-rating-of-0-17/2027990.html.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.